(isoquinolin-5-yl)carbamic acid phenyl ester | 628721-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: (isoquinolin-5-yl)carbamic acid phenyl ester
• 英文别名: isoquinolin-5-yl-carbamic acid phenyl ester；isoquinolin-5-ylcarbamic acid phenyl ester；phenyl N-(isoquinolin-5-yl)carbamate；phenyl isoquinolin-5-ylcarbamate；phenyl N-(5-isoquinolinyl)carbamate；phenyl N-isoquinolin-5-ylcarbamate
• CAS: 628721-45-9
• 化学式: C₁₆H₁₂N₂O₂
• 分子量: 264.283
• InChiKey: LYFSVAKNESEZCP-UHFFFAOYSA-N

物化性质

• 沸点：
  434.9±27.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(三氟甲基)苯乙胺 、 (isoquinolin-5-yl)carbamic acid phenyl ester 以 二甲基亚砜 为溶剂， 生成 1-异喹啉-5-基-3-[2-[3-(三氟甲基)苯基]乙基]脲
  参考文献：
  名称：

  N-Isoquinolin-5-yl-N′-aralkyl-urea and -amide antagonists of human vanilloid receptor 1

  摘要：

  Starting from a low micromolar agonist lead identified by high-throughput screening, series of N-isoquinolin-5-yl-N'-aralkyl ureas and analogous amides were developed as potent antagonists of human vanilloid receptor 1 (VR1). The synthesis and structure-activity relationships (SAR) of the series are described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.038
• 作为产物：
  描述：

  5-硝基异喹啉 在 吡啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 (isoquinolin-5-yl)carbamic acid phenyl ester
  参考文献：
  名称：

  化合物、制备方法及其用途

  摘要：

  本发明涉及药物化学领域，特别涉及化合物、制备方法及其用途。本发明涉及通式Ⅰ所示化合物及其盐，这类化合物为TRPV1拮抗剂，有较好的镇痛作用，本发明还涉及该类化合物的制备方法及含有它们的药物制剂，以及该类化合物和其药用组合物在治疗疼痛中的应用。

  公开号：

  CN105906564B

文献信息

• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS À BASE D'URÉE À SUBSTITUTION HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068452A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• Identification and Biological Evaluation of 4-(3-Trifluoromethylpyridin-2-yl)piperazine-1-carboxylic Acid (5-Trifluoromethylpyridin-2-yl)amide, a High Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist
  作者：Devin M. Swanson、Adrienne E. Dubin、Chandra Shah、Nadia Nasser、Leon Chang、Scott L. Dax、Michele Jetter、J. Guy Breitenbucher、Changlu Liu、Curt Mazur、Brian Lord、Lisa Gonzales、Kenway Hoey、Michele Rizzolio、Michael Bogenstaetter、Ellen E. Codd、Doo H. Lee、Sui-Po Zhang、Sandra R. Chaplan、Nicholas I. Carruthers

  DOI：10.1021/jm0495071

  日期：2005.3.1

  High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas (3) as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified the essential pharmacophoric elements for antagonism that permitted further optimization via targeted synthesis to provide a potent orally bioavailable

  使用重组人TRPV1受体的高通量筛选用于鉴定一系列吡啶基哌嗪脲（3）作为TRPV1香草受体配体。通过平行合成对结构-活性关系的探索，确定了拮抗作用的基本药效学元素，可以通过靶向合成进一步优化以提供有效的口服生物利用度和选择性的TRPV1调节剂41，在几种体内模型中具有活性。
• [EN] 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS<br/>[FR] DÉRIVÉS DE 4,5-DIHYDROISOXAZOLE UTILISÉS COMME INHIBITEURS DE NAMPT
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014111871A1

  公开（公告）日：2014-07-24

  The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

  本发明提供了式(I)的取代4,5-二氢异噁唑衍生物，可能在治疗上有用，更具体地是NAMPT抑制剂，其中R1、R2、Y、X、“Het”和“p”的含义如规范中所述，并且它们的药学上可接受的盐，在哺乳动物中治疗和预防由尼古酰胺磷酸核糖转移酶(NAMPT)水平升高引起的疾病或紊乱。本发明还提供了化合物的制备以及包含式(I)的取代4,5-二氢异噁唑衍生物中至少一个或其药学上可接受的盐或立体异构体或N-氧化物的制药配方。
• Aminotetralin-derived urea modulators of vanilloid VR1 receptor
  申请人：——

  公开号：US20030236280A1

  公开（公告）日：2003-12-25

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to &bgr;-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

  该发明涉及辣椒素受体VR1配体。更具体地，该发明涉及β-氨基四氢萘衍生的脲类化合物，它们是VR1的有效拮抗剂或激动剂，对于治疗和预防哺乳动物的炎症和其他疼痛症状具有用处。
• COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20190194137A1

  公开（公告）日：2019-06-27

  A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(═Z)—, wherein Z is N—CN, NH, NR 4 , NCOR 4 , NCONR 4 R 5 , NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH 2 , —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR 4 , —CONHR 4 , —CONHCH 2 -aryl, —CONR 4 CH 2 -aryl, —NHCOR 4 , halogen, halogened alkyl, -alkyl-OR 4 , -alkyl-ONO 2 , alkyl-ONO 2 , —OCOOR 4 , —O(C═O)-aryl, —CHR 4 OH, —CH 2 OH, —CH 2 O(C═O)-aryl, —CH 2 O(C═O)—R 4 , —CHR 4 O(C═O)-aryl, —CHR 4 O(C═O)—R 4 , unsaturated carboxylic ester, substituted alkynyl, —NHSO 2 R 4 , —SO 2 R 4 , —SO 2 NHR 4 , or —SO 2 NR 4 R 5 , or Y and J bond together to form a carbocylic or aromatic ring, wherein R 4 and R 5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NR 6 R 7 , —S(O) 0-2 -(alkyl-NR 6 R 7 ). R 1 , R 2 and R 3 are H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO 2 , or NR 8 R 9 .

  提供公式(I)的化合物或其药用盐。在公式(I)中，Ar是吲唑，5-异喹啉，6-异喹啉或它们的N-氧化物。X为—C(═Z)—，其中Z为N—CN，NH，NR4，NCOR4，NCONR4R5，NCO-芳基，S或O。Y和J独立地为H，烷基，芳基，氨基烷基，—NH2，—CN，—OH，—O-烷基，—O-芳基，—COOH，—COOR4，—CONHR4，—CONHCH2-芳基，—CONR4CH2-芳基，—NHCOR4，卤素，卤代烷基，-烷基-OR4，-烷基-ONO2，烷基-ONO2，—OCOOR4，—O(C═O)-芳基，—CHR4OH，—CH2OH，—CH2O(C═O)-芳基，—CH2O(C═O)—R4，—CHR4O(C═O)-芳基，—CHR4O(C═O)—R4，不饱和羧酸酯，取代炔烃基，—NHSO2R4，—SO2R4，—SO2NHR4或—SO2NR4R5，或Y和J结合在一起形成环，其中R4和R5独立地为H，取代的C1-C6烷基，取代的芳基，环烷基，烷基芳基，-烷基-NR6R7，—S(O)0-2-(烷基-NR6R7)。R1，R2和R3为H，C1-C6烷基，环烷基，芳基，烷基芳基，烷基杂芳基，烷基杂环，其中任意一个可以选择地取代一个或多个OH，NO2或NR8R9。